259 related articles for article (PubMed ID: 21815697)
1. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach.
Garçon N; Morel S; Didierlaurent A; Descamps D; Wettendorff M; Van Mechelen M
BioDrugs; 2011 Aug; 25(4):217-26. PubMed ID: 21815697
[TBL] [Abstract][Full Text] [Related]
2. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
McKeage K; Romanowski B
BioDrugs; 2011 Aug; 25(4):265-9. PubMed ID: 21815703
[TBL] [Abstract][Full Text] [Related]
4. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile.
Garçon N; Wettendorff M; Van Mechelen M
Expert Opin Biol Ther; 2011 May; 11(5):667-77. PubMed ID: 21457083
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
[TBL] [Abstract][Full Text] [Related]
6. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
[TBL] [Abstract][Full Text] [Related]
7. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
McKeage K; Romanowski B
Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
[TBL] [Abstract][Full Text] [Related]
8. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
Giannini SL; Hanon E; Moris P; Van Mechelen M; Morel S; Dessy F; Fourneau MA; Colau B; Suzich J; Losonksy G; Martin MT; Dubin G; Wettendorff MA
Vaccine; 2006 Aug; 24(33-34):5937-49. PubMed ID: 16828940
[TBL] [Abstract][Full Text] [Related]
9. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years.
Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F
J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial.
Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F
Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002
[TBL] [Abstract][Full Text] [Related]
11. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D
Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
[TBL] [Abstract][Full Text] [Related]
13. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
14. Preclinical development of AS04.
Garçon N
Methods Mol Biol; 2010; 626():15-27. PubMed ID: 20099118
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical safety assessment of single and repeated intramuscular administration of a human papillomavirus-16/18 vaccine in rabbits and rats.
Segal L; Morelle D; Kaaber K; Destexhe E; Garçon N
J Appl Toxicol; 2015 Dec; 35(12):1577-85. PubMed ID: 25752809
[TBL] [Abstract][Full Text] [Related]
16. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.
Leroux-Roels G; Haelterman E; Maes C; Levy J; De Boever F; Licini L; David MP; Dobbelaere K; Descamps D
Clin Vaccine Immunol; 2011 Sep; 18(9):1510-8. PubMed ID: 21734063
[TBL] [Abstract][Full Text] [Related]
18. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: follow-up through Month 48 in a Phase III randomized study.
Einstein MH; Levin MJ; Chatterjee A; Chakhtoura N; Takacs P; Catteau G; Dessy FJ; Moris P; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3455-65. PubMed ID: 25483700
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years.
Kim YJ; Kim KT; Kim JH; Cha SD; Kim JW; Bae DS; Nam JH; Ahn WS; Choi HS; Ng T; Bi D; OK JJ; Descamps D; Bock HL
J Korean Med Sci; 2010 Aug; 25(8):1197-204. PubMed ID: 20676333
[TBL] [Abstract][Full Text] [Related]
20. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
Romanowski B; Schwarz TF; Ferguson L; Peters K; Dionne M; Behre U; Schulze K; Hillemanns P; Suryakiran P; Thomas F; Struyf F
Hum Vaccin Immunother; 2016; 12(1):20-9. PubMed ID: 26176261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
